Super Fast Pharma - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Super Fast Pharma
British racing car company and GlaxoSmithKline team up on a winning formula for innovation.


Pharmaceutical Technology
pp. 14


Rich Whitworth
Partnerships and strategic agreements are common in the pharma industry. But one particular announcement last month gave me cause to raise my eyebrows and smile.

I like fast cars and so too, it would seem, does GlaxoSmithKline's CEO Andrew Witty because the company is embarking on a long-term strategic partnership with the McLaren group, which is best known for its Formula 1 racing cars. The phrase "best of British" springs to mind and both companies seem extremely proud of the partnership.

The aim for GSK? Applying McLaren's engineering and technical expertise to production lines to reduce breakdowns and improve costs, amongst other things.

A state-of-the-art facility planned for 2013 called The McLaren GSK Centre for Applied Performance will allow scientists, engineers, and technologists from both camps to share ideas and collaborate on innovative, dynamic, and exciting joint working projects.

The R&D organization will examine whether real-time monitoring technologies can be applied to human studies. Meanwhile, the GSK Consumer Healthcare business will work with McLaren's "Mission Control" unit to enable faster responses to competitor activity and customer needs.

Some might say that it smacks of a marketing stunt, but which pharma company wouldn't want to be associated with such a fast-paced, exciting, technologically advanced, continually improving world?

What next? Sanofi and Red Bull Racing? The race to the checkered flag is on!

Rich Whitworth is an editor of Pharmaceutical Technology.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here